Formulation of bovine respiratory syncytial virus fusion protein with CpG oligodeoxynucleotide, cationic host defence peptide and polyphosphazene enhances humoral and cellular responses and induces a protective type 1 immune response in mice.

Respiratory syncytial virus (RSV) is the leading cause of serious respiratory tract disease in children and calves; however, RSV vaccine development has been slow due to early observations that formalin-inactivated vaccines induced Th2-type immune responses and led to disease enhancement upon subsequent exposure. Hence, there is a need for novel adjuvants that will promote a protective Th1-type or balanced immune response against RSV. CpG oligodeoxynucleotides (ODNs), indolicidin, and polyphosphazene were examined for their ability to enhance antigen-specific immune responses and influence the Th-bias when co-formulated with a recombinant truncated bovine RSV (BRSV) fusion protein (DeltaF). Mice immunized with DeltaF co-formulated with CpG ODN, indolicidin, and polyphosphazene (DeltaF/CpG/indol/PP) developed higher levels of DeltaF-specific serum IgG, IgG1 and IgG2a antibodies when compared with DeltaF alone, and displayed an increase in the frequency of gamma interferon-secreting cells and decreased interleukin (IL)-5 production by in vitro restimulated splenocytes, characteristic of a Th1 immune response. These results were observed in both C57BL/6 and BALB/c strains of mice. When evaluated in a BRSV challenge model, mice immunized with DeltaF/CpG/indol/PP developed significantly higher levels of BRSV-neutralizing serum antibodies than mice immunized with the DeltaF protein alone, and displayed significantly less pulmonary IL-4, IL-5, IL-13 and eotaxin and reduced eosinophilia after challenge. These results suggest that co-formulation of DeltaF with CpG ODN, host defence peptide and polyphosphazene may result in a safe and effective vaccine for the prevention of BRSV and may have implications for the development of novel human RSV vaccines.

[1]  G. Prince,et al.  Immunoprotective Activity and Safety of a RespiratorySyncytial Virus Vaccine: Mucosal Delivery of Fusion Glycoprotein with aCpG OligodeoxynucleotideAdjuvant , 2003, Journal of Virology.

[2]  B. Moss,et al.  T cell responses to respiratory syncytial virus fusion and attachment proteins in human peripheral blood mononuclear cells. , 2006, Viral immunology.

[3]  R. Ward,et al.  Effects of different adjuvants on rotavirus antibody responses and protection in mice following intramuscular immunization with inactivated rotavirus. , 1999, Vaccine.

[4]  A. Andrianov,et al.  Polyphosphazene polyelectrolytes: a link between the formation of noncovalent complexes with antigenic proteins and immunostimulating activity. , 2005, Biomacromolecules.

[5]  L. Larsen,et al.  Replication and Clearance of Respiratory Syncytial Virus , 2002, The American Journal of Pathology.

[6]  S. Beaucage,et al.  CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[7]  R. Hancock,et al.  Immunomodulatory Activities of Small Host Defense Peptides , 2005, Antimicrobial Agents and Chemotherapy.

[8]  R. Hancock,et al.  Cationic host defense (antimicrobial) peptides. , 2006, Current opinion in immunology.

[9]  Yvonne Perrie,et al.  Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens. , 2008, International journal of pharmaceutics.

[10]  L. A. Ball,et al.  Human and murine cytotoxic T cells specific to respiratory syncytial virus recognize the viral nucleoprotein (N), but not the major glycoprotein (G), expressed by vaccinia virus recombinants. , 1986, Journal of immunology.

[11]  K. Barnhart,et al.  CpG motifs as immune adjuvants. , 1999, Vaccine.

[12]  Andrianov,et al.  Protein release from polyphosphazene matrices. , 1998, Advanced drug delivery reviews.

[13]  S. Rankin,et al.  Eotaxin induces a rapid release of eosinophils and their progenitors from the bone marrow. , 1998, Blood.

[14]  L. Babiuk,et al.  Intranasal immunization of mice with a formalin-inactivated bovine respiratory syncytial virus vaccine co-formulated with CpG oligodeoxynucleotides and polyphosphazenes results in enhanced protection. , 2008, The Journal of general virology.

[15]  B. Kjellman,et al.  Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7. , 2000, American journal of respiratory and critical care medicine.

[16]  R. Baggs,et al.  Formulation of the purified fusion protein of respiratory syncytial virus with the saponin QS-21 induces protective immune responses in Balb/c mice that are similar to those generated by experimental infection. , 1995, Vaccine.

[17]  B A Askonas,et al.  Cytotoxic T cells clear virus but augment lung pathology in mice infected with respiratory syncytial virus , 1988, The Journal of experimental medicine.

[18]  F. Schelcher,et al.  Human and bovine respiratory syncytial virus vaccine research and development. , 2008, Comparative immunology, microbiology and infectious diseases.

[19]  P. Collins,et al.  The fusion glycoproteins of human respiratory syncytial virus of subgroups A and B: sequence conservation provides a structural basis for antigenic relatedness. , 1988, The Journal of general virology.

[20]  Ronald K. Taylor,et al.  Evaluation of Cholera Vaccines Formulated with Toxin-Coregulated Pilin Peptide Plus Polymer Adjuvant in Mice , 2001, Infection and Immunity.

[21]  L. Gershwin.  Bovine respiratory syncytial virus infection: immunopathogenic mechanisms , 2007, Animal Health Research Reviews.

[22]  E. Walsh,et al.  Group-specific serum antibody responses in children with primary and recurrent respiratory syncytial virus infections. , 1991, The Journal of infectious diseases.

[23]  L. Babiuk,et al.  The novel adjuvant combination of CpG ODN, indolicidin and polyphosphazene induces potent antibody- and cell-mediated immune responses in mice. , 2009, Vaccine.

[24]  Wayne L. Smith,et al.  Indolicidin, a novel bactericidal tridecapeptide amide from neutrophils. , 1992, The Journal of biological chemistry.

[25]  W. V. D. van der Poel,et al.  Respiratory syncytial virus infections in human beings and in cattle. , 1994, The Journal of infection.

[26]  G. Bishop,et al.  CpG motifs in bacterial DNA trigger direct B-cell activation , 1995, Nature.

[27]  A. Andrianov,et al.  Poly[di(carboxylatophenoxy)phosphazene] (PCPP) is a potent immunoadjuvant for an influenza vaccine. , 1998, Vaccine.

[28]  S. Pillai,et al.  The pulmonary immune response of Balb/c mice vaccinated with the fusion protein of respiratory syncytial virus. , 1994, Vaccine.

[29]  D. Meyerholz,et al.  IL-13 Is Required for Eosinophil Entry into the Lung during Respiratory Syncytial Virus Vaccine-Enhanced Disease1 , 2008, The Journal of Immunology.

[30]  B. García-Barreno,et al.  Antigenic Structure of Human Respiratory Syncytial Virus Fusion Glycoprotein , 1998, Journal of Virology.

[31]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.

[32]  T. Braciale,et al.  Virus-specific CD8+ T Lymphocytes Downregulate T Helper Cell Type 2 Cytokine Secretion and Pulmonary Eosinophilia during Experimental Murine Respiratory Syncytial Virus Infection , 1997, The Journal of experimental medicine.

[33]  L. Babiuk,et al.  CpG-containing oligodeoxynucleotides, in combination with conventional adjuvants, enhance the magnitude and change the bias of the immune responses to a herpesvirus glycoprotein. , 2002, Vaccine.

[34]  E. Walsh,et al.  Immunity to and frequency of reinfection with respiratory syncytial virus. , 1991, The Journal of infectious diseases.

[35]  A. Krieg,et al.  Enhancement of infectious disease vaccines through TLR9-dependent recognition of CpG DNA. , 2006, Current topics in microbiology and immunology.

[36]  P. Openshaw,et al.  CD4+ T cells clear virus but augment disease in mice infected with respiratory syncytial virus. Comparison with the effects of CD8+ T cells , 1992, Clinical and experimental immunology.

[37]  L. Anderson,et al.  Respiratory synctial virus infection in BALB/c mice previously immunized with formalin-inactivated virus induces enhanced pulmonary inflammatory response with a predominant Th2-like cytokine pattern , 1996, Journal of virology.

[38]  W. Schmidt,et al.  Poly-L-arginine synergizes with oligodeoxynucleotides containing CpG-motifs (CpG-ODN) for enhanced and prolonged immune responses and prevents the CpG-ODN-induced systemic release of pro-inflammatory cytokines. , 2002, Vaccine.

[39]  R. Holman,et al.  Bronchiolitis-associated hospitalizations among US children, 1980-1996. , 1999, JAMA.

[40]  J. Smith,et al.  CpG containing oligodeoxynucleotides are potent adjuvants for parenteral vaccination with the fusion (F) protein of respiratory syncytial virus (RSV). , 2001, Vaccine.

[41]  W. P. Glezen,et al.  Risk of primary infection and reinfection with respiratory syncytial virus. , 1986, American journal of diseases of children.

[42]  B. Graham,et al.  Immune-mediated disease pathogenesis in respiratory syncytial virus infection. , 2000, Immunopharmacology.

[43]  P. Collins,et al.  Nucleotide sequence of the gene encoding the fusion (F) glycoprotein of human respiratory syncytial virus. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[44]  D. Klinman.  Immunotherapeutic uses of CpG oligodeoxynucleotides , 2004, Nature Reviews Immunology.

[45]  L. Babiuk,et al.  Immunogenicity of Bovine Herpes virus 1 Glycoprotein D in Mice: Effect of Antigen Form on the Induction of Cellular and Humoral Immune Responses , 1996 .

[46]  L. Babiuk,et al.  Poly[di(sodium carboxylatoethylphenoxy)phosphazene] (PCEP) is a potent enhancer of mixed Th1/Th2 immune responses in mice immunized with influenza virus antigens. , 2007, Vaccine.

[47]  J. Valarcher,et al.  Bovine respiratory syncytial virus infection. , 2007, Veterinary research.

[48]  R. Karron,et al.  Respiratory syncytial virus and metapneumovirus , 2007 .

[49]  J. Langedijk,et al.  Vaccine-Induced Immunopathology during Bovine Respiratory Syncytial Virus Infection: Exploring the Parameters of Pathogenesis , 2003, Journal of Virology.

[50]  J. Schlesinger,et al.  Protection from respiratory syncytial virus infection in cotton rats by passive transfer of monoclonal antibodies , 1984, Infection and immunity.

[51]  R. Parker,et al.  IL-13 Is Sufficient for Respiratory Syncytial Virus G Glycoprotein-Induced Eosinophilia After Respiratory Syncytial Virus Challenge 1 , 2003, The Journal of Immunology.

[52]  Viral subunit vaccines , 1991, The Lancet.

[53]  M. Buschle,et al.  The artificial antimicrobial peptide KLKLLLLLKLK induces predominantly a TH2-type immune response to co-injected antigens. , 2004, Vaccine.

[54]  R. Hancock,et al.  Cationic peptides: effectors in innate immunity and novel antimicrobials. , 2001, The Lancet. Infectious diseases.

[55]  A. Krieg,et al.  CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. , 1998, Journal of immunology.

[56]  B. Graham,et al.  The Role of IFN in Respiratory Syncytial Virus Pathogenesis , 2002, The Journal of Immunology.

[57]  B. Björkstén,et al.  Asthma and immunoglobulin E antibodies after respiratory syncytial virus bronchiolitis: a prospective cohort study with matched controls. , 1995, Pediatrics.

[58]  G. Plosker,et al.  Palivizumab: a review of its use as prophylaxis for serious respiratory syncytial virus infection. , 2004, Paediatric drugs.

[59]  K. Conzelmann,et al.  Cleavage at the Furin Consensus Sequence RAR/KR109 and Presence of the Intervening Peptide of the Respiratory Syncytial Virus Fusion Protein Are Dispensable for Virus Replication in Cell Culture , 2002, Journal of Virology.

[60]  W. Mitzner,et al.  Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease , 2009, Nature Medicine.

[61]  E. Walsh.  Humoral, mucosal, and cellular immune response to topical immunization with a subunit respiratory syncytial virus vaccine. , 1994, The Journal of infectious diseases.

[62]  S. Rankin,et al.  Eotaxin and eosinophil recruitment: implications for human disease. , 2000, Molecular medicine today.

[63]  F. Yarovinsky,et al.  Mouse Cathelin-Related Antimicrobial Peptide Chemoattracts Leukocytes Using Formyl Peptide Receptor-Like 1/Mouse Formyl Peptide Receptor-Like 2 as the Receptor and Acts as an Immune Adjuvant1 , 2005, The Journal of Immunology.

[64]  A. Krieg,et al.  Therapeutic potential of Toll-like receptor 9 activation , 2006, Nature Reviews Drug Discovery.

[65]  A. Andrianov,et al.  Synthesis and biologically relevant properties of polyphosphazene polyacids. , 2004, Biomacromolecules.

[66]  G. Taylor,et al.  Monoclonal antibodies protect against respiratory syncytial virus infection in mice. , 1984, Immunology.

[67]  S. J. Hoffman,et al.  A Role for Immune Complexes in Enhanced Respiratory Syncytial Virus Disease , 2002, The Journal of experimental medicine.

[68]  Xiao-tong Ma,et al.  LL-37 enhances adaptive antitumor immune response in a murine model when genetically fused with M-CSFR (J6-1) DNA vaccine. , 2005, Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis.